ArticleScientific reports2026
Protective effects of Astragalus membranaceus polysaccharide against aluminum oxide nanoparticle-induced growth retardation and oxidative-immunological disruption in Oreochromis niloticus.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although the toxicity of aluminum-based nanoparticles (Al2O3-NPs) in fish has been widely studied, strategies to mitigate their harmful effects remain limited. Moreover, the modulatory role of Astragalus membranaceus polysaccharides (APS) under this toxic stress is still poorly understood, despite the widespread presence of Al2O3-NPs in aquatic ecosystems and the need for effective mitigation strategies for sustainable aquaculture. In this study, Oreochromis niloticus was exposed to Al2O3-NPs (10 mg/L) with or without dietary APS (1.5 or 3 mg/kg) for four weeks. A total of 270 fish (initial weight = 25.28 ± 0.086 g) were randomly distributed into six triplicate groups (n = 15 per group) as control, APS (1.5 mg/kg–3 mg/kg), Al2O3-NPs, and two co-treated groups (Al2O3-NPs + APS). Al2O3-NPs exposure showed significant effects on growth performance compared to the control group (P < 0.05), as shown by the decrease in final weight (FW: -9.4%), weight gain (WG: − 21.4%), specific growth rate (SGR: -17.1%), along with an increase in feed conversion ratio (FCR: + 16.9%). Liver function was severely affected, as evidenced by an increase in ALT levels (+ 39%) and decrease in total protein (− 26.5%) and IgM levels (− 19.3%) (P < 0.05). In addition, the expression of antioxidant-related genes, such as CAT and SOD, was downregulated, while the expression of pro-inflammatory cytokines, such as TNF-β and IL-1β, as well as stress-related gene, such as MT, was upregulated in the liver and gills (P < 0.05). Histopathological examination showed noticeable degenerative and necrotic changes in the liver, kidney, muscle, gill, and spleen tissues. Co-treatment with APS, particularly at 3 mg/kg, significantly improved growth parameters (FW, 20.3% increase; WG, 53.1% increase; and SGR, 38.8% increase) (P < 0.05), ameliorated hepatic and renal histopathological changes, restored antioxidant gene expression and normalized inflammatory mediators compared with the Al2O3-NPs-exposed group. Compared with the Al2O3-NPs–exposed group, the survival rate increased by 5.3%, ALT levels decreased by 60.1%, while total protein and IgM levels increased by 29.6% and 8.9%, respectively. Overall, APS supplementation effectively mitigated Al2O3-NPs-induced toxicity in O. niloticus by regulating antioxidant capacity, suppressing inflammatory responses, and improving tissue structure, highlighting its potential as an eco-friendly functional food additive to protect fish health under nano-toxic stress.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.